Upgrade to SI Premium - Free Trial

BMO Capital Keeps AbbVie (ABBV) at 'Market Perform'; Says Humira Solid in Q2, but Questions Remain

July 29, 2016 11:54 AM
BMO Capital affirms AbbVie (NYSE: ABBV) at Market Perform with a price target of $66 following Q2 results out earlier ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles